Inductive topped the OpenADMET CYP Direct Inhibition Challenge, marking its fourth straight win in AI drug discovery benchmarks while besting industry peers NVIDIA and Recursion.
Recursion placed fourth out of more than 270 eligible participants in the OpenADMET CYP Direct Inhibition Blind Challenge, behind winner Inductive and third-place NVIDIA. A lower benchmark ranking in AI-driven ADMET prediction is a modest negative signal for Recursion's competitive positioning in AI drug discovery, though a single benchmark placement without financial figures rarely moves the share price.
The article gives no financial figures or pipeline impact; it only ranks Recursion fourth in a blind ADMET prediction challenge won by Inductive.
NVIDIA placed third among more than 270 participants in the OpenADMET CYP Direct Inhibition Blind Challenge, behind winner Inductive. This is a passing competitive mention for NVIDIA, whose core business lies well beyond ADMET prediction software, and the article provides no financial or product figures tied to the result.
Inductive secured its fourth consecutive victory in the OpenADMET CYP Direct Inhibition Blind Challenge, outperforming over 270 participants. The competition, which tested predictive models on 750 compounds, saw NVIDIA and Recursion Pharmaceuticals take third and fourth place, respectively. Inductive's Beacon models continue to lead in AI-driven drug discovery benchmarks.
The challenge serves as a blind benchmark for AI models to predict how small molecule drugs interact with Cytochrome P450 enzymes, a critical step in identifying drug-drug interaction liabilities early in the discovery process.
The benchmark result is a technical performance metric and does not provide financial guidance or indicate a material change in Recursion's business operations or pipeline development.